How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic Compounds
CEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions of people suffering around the globe.
CEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions of people suffering around the globe.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.